Annette Wundes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1741055/publications.pdf

Version: 2024-02-01

		1040056	996975
15	403	9	15
papers	citations	h-index	g-index
15	15	15	579
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the PhaseÂ3 EVOLVE-MS-1 Study. Advances in Therapy, 2022, 39, 1810-1831.	2.9	16
2	Encephalitis and Myelitis in a Young Woman. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1026.	6.0	1
3	Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1.0 – Fatigue (MS) 8a. Multiple Sclerosis and Related Disorders, 2021, 54, 103117.	2.0	10
4	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199399.	3.5	12
5	Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis Journal, 2020, 26, 1729-1739.	3.0	41
6	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. CNS Drugs, 2020, 34, 185-196.	5.9	80
7	Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study. Multiple Sclerosis Journal, 2019, 25, 1162-1169.	3.0	17
8	Improving the quality of depression and pain care in multiple sclerosis using collaborative care: The MS-care trial protocol. Contemporary Clinical Trials, 2018, 64, 219-229.	1.8	15
9	FDG-PET abnormalities leading to the diagnosis of an unusual case of probable neurosarcoidosis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e506.	6.0	5
10	Brain pathology of a patient 7 years after autologous hematopoietic stem cell transplantation for multiple sclerosis. Journal of the Neurological Sciences, 2017, 373, 339-341.	0.6	3
11	Accelerating international MS care through videoconference-based education and case consultation. Neurology, 2016, 87, e8-e10.	1.1	1
12	High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS). JAMA Neurology, 2015, 72, 159.	9.0	158
13	Experiences and Perspectives of Pregnancy in Women with Multiple Sclerosis. Sexuality and Disability, 2015, 33, 47-52.	1.0	2
14	What Do Healthcare Providers Advise Women with Multiple Sclerosis Regarding Pregnancy?. Multiple Sclerosis International, 2014, 2014, 1-5.	0.8	18
15	Contribution of intangible costs to the economic burden of multiple sclerosis. Journal of Medical Economics, 2010, 13, 626-632.	2.1	24